| Disease | NONSIGNIFIFCANT). PURE ISOFLAVONOIDS DID NOT ALLEVIATE SUBJECTIVE MENOPAUSAL SYMPTOMS IN BREAST CANCER PATIENTS.
TOLERATED AND CAUSED NO CHANGES IN LIVER ENZYMES, CREATININE, BODY MASS INDEX, OR BLOOD PRESSURE. OF THE 56 WOMEN, 25 (44.6%) PREFERRED THE PHYTOESTROGEN REGIMEN, 15 PREFERRED THE PLACEBO (26.8%), AND 16 (28.6%) REPORTED NO PREFERENCE(
THE QUALITY OF LIFE PARAMETERS (WORKING CAPACITY, MOOD CHANGES) WERE UNAFFECTED BY PHYTOESTROGEN. IN ADDITION, THE PHYTOESTROGEN REGIMEN CAUSED NO CHANGES IN FSH, LH, ESTADIOL, OR SEX HORMONE-BINDING GLOBULIN. PHYTOESTROGEN TREATMENT WAS WELL
OF PHYTOESTROGENS (DAIDZEIN, GENISTEIN, EQUOL) 19-TO 106-FOLD. THE KUPPERMAN INDEX WAS REDUCED BY 4.2+/-9.6 (MEAN +/- STANDARD DEVIATION) (15.5%) DURING PHYTOESTROGEN USE AND SIMILARY BY 4.0+/-8.1 (14.4%) DURING PLACEBO USE (P NONSIGNIFICANT).
PHYTOESTROGENS, FOLLICLE-STIMULATING HORMONE (FSH), LUTEINIZING HORMONE (LH), ESTRADIOL, AND SEX-HORMONE-BINDING GLOBULIN. LIVER ENZYMES AND CREATININE WERE ALSO ASSESSED AT EACH VISIT. THE PHYTOESTROGEN REGIMEN RAISED THE CIRULATING LEVELS
WOMEN COMPLETED THE STUDY. MENOPAUSAL SYMPTOMS WERE RECORDED ON THE KUPPERMAN INDEX AND THE VISUAL ANALOGUE SCALE, AND WORKING CAPACITY AND MOOD CHANGES WERE ASSESSED VIA VALIDATE QUESTIONNARIES. IN ADDITION, WE FOLLOWED THE LEVELS OF
SIXTY-TWO POSTMENOPAUSAL SYMPTOMATIC WOMEN WERE RANDOMIZED TO USE EITHER PHYTOESTROGEN (TABLETS CONTAINING 114 MG OF ISOFLAVONOIDS) OR A PLACEBO FOR 3 MONTHS; THE TREATMENT REGIMENTS WERE REVERSED AFTER A 2-MONTH WASHOUT PERIOD. FIFTY-SIX |